labetalol has been researched along with Cardiac Failure in 21 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the effects of the beta1-beta2-alpha1-blocker, labetalol, in the congestive heart failure (CHF) model induced by aortic constriction in the guinea pig." | 7.71 | Early anti-remodeling effect of labetalol in the congestive heart failure model induced by aortic constriction in the guinea pig. ( Bellissant, E; Goineau, S; Guillo, P; Pape, D; Ramée, MP, 2002) |
| "Labetalol is used to treat hypertensive crisis in women with preeclampsia." | 7.69 | Use of glucagon to treat neonatal low-output congestive heart failure after maternal labetalol therapy. ( Guillet, R; Stevens, TP, 1995) |
| "To investigate the safety of labetalol in the treatment of hypertension in patients with heart failure, sixteen hypertensive patients with a history of congestive heart failure and an ejection fraction at rest less than 45%, had measurements of ejection fraction and cardiac output by first pass radionuclide angiography at baseline, at the end of 2 weeks maintenance with labetalol (titrated to the effective antihypertensive dose of 200-1600 mg daily), and in the post-treatment placebo period." | 7.67 | Hemodynamic effects of labetalol in patients with combined hypertension and left ventricular failure. ( Berger, H; Cubbon, J; Escala, E; Johnson, LL; Jones, RH; Ramanathan, KB; Sciacca, R, 1988) |
| " Oral nifedipine is now considered an alternative first-line therapy, along with intravenous hydralazine and labetalol for women presenting with pre-eclampsia." | 4.98 | Focused Update on Pharmacologic Management of Hypertensive Emergencies. ( Broscious, R; Devabhakthuni, S; Noel, ZR; Watson, K, 2018) |
| " It has also been used intravenously in phaeochromocytoma, tetanus, clonidine withdrawal, and as an adjunct to halothane to produce hypotensive anaesthesia." | 4.76 | Combined alpha- and beta-receptor inhibition in the treatment of hypertension. ( Prichard, BN, 1984) |
| "We investigated the effects of the beta1-beta2-alpha1-blocker, labetalol, in the congestive heart failure (CHF) model induced by aortic constriction in the guinea pig." | 3.71 | Early anti-remodeling effect of labetalol in the congestive heart failure model induced by aortic constriction in the guinea pig. ( Bellissant, E; Goineau, S; Guillo, P; Pape, D; Ramée, MP, 2002) |
| "Labetalol is used to treat hypertensive crisis in women with preeclampsia." | 3.69 | Use of glucagon to treat neonatal low-output congestive heart failure after maternal labetalol therapy. ( Guillet, R; Stevens, TP, 1995) |
| "To investigate the safety of labetalol in the treatment of hypertension in patients with heart failure, sixteen hypertensive patients with a history of congestive heart failure and an ejection fraction at rest less than 45%, had measurements of ejection fraction and cardiac output by first pass radionuclide angiography at baseline, at the end of 2 weeks maintenance with labetalol (titrated to the effective antihypertensive dose of 200-1600 mg daily), and in the post-treatment placebo period." | 3.67 | Hemodynamic effects of labetalol in patients with combined hypertension and left ventricular failure. ( Berger, H; Cubbon, J; Escala, E; Johnson, LL; Jones, RH; Ramanathan, KB; Sciacca, R, 1988) |
| "A patient treated for hypertension with labetalol developed left ventricular failure." | 3.66 | Left ventricular failure with labetalol. ( Bayley, TJ; Frais, MA, 1979) |
| " Hepatic pharmacokinetic modelling was performed with a two-phase physiologically-based organ pharmacokinetic model with the vascular space and dispersion evaluated with the MID technique." | 1.38 | Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage. ( Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Weiss, M; Zhang, Q, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (42.86) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 5 (23.81) | 29.6817 |
| 2010's | 4 (19.05) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, H | 1 |
| Sim, JJ | 1 |
| Shi, J | 1 |
| Shaw, SF | 1 |
| Lee, MS | 2 |
| Neyer, JR | 1 |
| Kovesdy, CP | 1 |
| Kalantar-Zadeh, K | 1 |
| Jacobsen, SJ | 1 |
| Duan, L | 1 |
| Ng, A | 1 |
| Chen, W | 1 |
| Spencer, HT | 1 |
| Nguyen, J | 1 |
| Shen, AY | 1 |
| Watson, K | 1 |
| Broscious, R | 1 |
| Devabhakthuni, S | 1 |
| Noel, ZR | 1 |
| Jacobson, AF | 1 |
| Travin, MI | 1 |
| Manrique, C | 1 |
| Giles, TD | 1 |
| Ferdinand, KC | 1 |
| Sowers, JR | 1 |
| Li, P | 1 |
| Robertson, TA | 1 |
| Zhang, Q | 1 |
| Fletcher, LM | 1 |
| Crawford, DH | 1 |
| Weiss, M | 1 |
| Roberts, MS | 1 |
| Kai, H | 1 |
| Imaizumi, T | 2 |
| Weber, MA | 1 |
| Mizuta, Y | 1 |
| Rubin, PC | 1 |
| Reid, JL | 1 |
| Prichard, BN | 1 |
| Bernard, R | 1 |
| Renard, M | 1 |
| El Matri, A | 1 |
| Kechrid, C | 1 |
| Larabi, M | 1 |
| Belkahia, C | 1 |
| Ben Ayed, H | 1 |
| Cohn, JN | 1 |
| Mehta, J | 1 |
| Francis, GS | 1 |
| Stevens, TP | 1 |
| Guillet, R | 1 |
| Pape, D | 1 |
| Goineau, S | 1 |
| Guillo, P | 1 |
| Ramée, MP | 1 |
| Bellissant, E | 1 |
| Frishman, W | 1 |
| Halprin, S | 1 |
| Frais, MA | 1 |
| Bayley, TJ | 1 |
| Strein, K | 1 |
| Sponer, G | 1 |
| Johnson, LL | 1 |
| Cubbon, J | 2 |
| Escala, E | 1 |
| Sciacca, R | 1 |
| Ramanathan, KB | 1 |
| Berger, H | 1 |
| Jones, RH | 1 |
| Kinhal, V | 1 |
| Kulkarni, A | 1 |
| Pozderac, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Alternative in Beta Blocker Intolerance; the ABBI Trial[NCT00893984] | Phase 4 | 6 participants (Actual) | Interventional | 2009-05-31 | Terminated (stopped due to Lack of patient recruitment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
Mild symptoms include weight gain, edema, and headaches (NCT00893984)
Timeframe: 30 Days
| Intervention | participants (Number) |
|---|---|
| Nebivolol | 1 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
8 reviews available for labetalol and Cardiac Failure
| Article | Year |
|---|---|
Focused Update on Pharmacologic Management of Hypertensive Emergencies.
Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Brain Ischemia; Emergencies; Enalapri | 2018 |
Impact of medications on mIBG uptake, with specific attention to the heart: Comprehensive review of the literature.
Topics: 3-Iodobenzylguanidine; Amines; Amiodarone; Animals; Anti-Arrhythmia Agents; Antidepressive Agents, T | 2015 |
Realities of newer beta-blockers for the management of hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Benzopyrans; Carbazoles; Carvedilol; Ethanolam | 2009 |
[Protective effect of alpha beta-blockers on hypertensive target-organ damage].
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive | 2004 |
The role of the new beta-blockers in treating cardiovascular disease.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans | 2005 |
[Alpha beta-blockers for patients with hypertension].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carv | 2006 |
Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthesia; Antihyp | 1984 |
Experimental and clinical pharmacology of carvedilol and other drugs combining vasodilation and beta-adrenoceptor antagonism in a single molecule.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Celiprolol; Coronary Disease; Heart Fa | 1990 |
1 trial available for labetalol and Cardiac Failure
| Article | Year |
|---|---|
Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 7. New horizons in beta-adrenoceptor blockade therapy: labetalol.
Topics: Arrhythmias, Cardiac; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Coronary Disease; Eth | 1979 |
12 other studies available for labetalol and Cardiac Failure
| Article | Year |
|---|---|
β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atenolol; Bisoprolol; Carvedilol; Cause of Dea | 2021 |
β-Blocker Exposure in Pregnancy and Risk of Fetal Cardiac Anomalies.
Topics: Adrenergic beta-Antagonists; Age Factors; Arrhythmias, Cardiac; Atenolol; Body Mass Index; Californi | 2017 |
Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage.
Topics: Adrenergic Antagonists; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2012 |
Alpha-blockers and converting enzyme inhibitors.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Heart Failure; Hu | 1983 |
[Heart failure and acute myocardial infarct. Current treatment].
Topics: Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Imidazoles; Labetalol; Myocardial Infarction; | 1983 |
[Combined captopril and labetalol treatment of malignant arterial hypertension (author's transl)].
Topics: Adult; Captopril; Drug Synergism; Drug Therapy, Combination; Ethanolamines; Female; Heart Failure; H | 1981 |
A review of the haemodynamic effects of labetalol in man.
Topics: Blood Pressure; Ethanolamines; Heart Failure; Heart Rate; Hemodynamics; Humans; Hypertension; Labeta | 1982 |
Use of glucagon to treat neonatal low-output congestive heart failure after maternal labetalol therapy.
Topics: Adult; Eclampsia; Female; Glucagon; Heart Failure; Humans; Infant, Newborn; Infant, Newborn, Disease | 1995 |
Early anti-remodeling effect of labetalol in the congestive heart failure model induced by aortic constriction in the guinea pig.
Topics: Adrenergic beta-Antagonists; Animals; Aorta; Aortic Valve Stenosis; Body Weight; Disease Models, Ani | 2002 |
Left ventricular failure with labetalol.
Topics: Adult; Ethanolamines; Heart Diseases; Heart Failure; Humans; Hypertension; Labetalol; Male | 1979 |
Hemodynamic effects of labetalol in patients with combined hypertension and left ventricular failure.
Topics: Angiography; Cardiac Output; Exercise Test; Female; Heart Failure; Hemodynamics; Humans; Hypertensio | 1988 |
Hemodynamic effects of dilevalol in patients with systemic hypertension and left ventricular dysfunction.
Topics: Aged; Exercise Test; Heart Failure; Heart Rate; Hemodynamics; Humans; Hypertension; Labetalol; Male; | 1989 |